High tibial osteotomy as a first step in knee preservationHigh tibial osteotomy repositions the tibia to shift weight-bearing from damaged inner knee cartilage to the healthier outer compartment. For younger, active patients, the procedure preserves the natural joint and potentially extends its working life by a decade or more.High tibial osteotomy repositions the tibia to shift weight-bearing from damaged inner knee cartilage to the healthier outer compartment. For younger, active patients, the procedure preserves the natural joint and potentially extends its working life by a decade or more.
Knee cartilage damage left untreated and when repair helpsCartilage lacks blood vessels, nerve fibres, and lymph channels, so repair cells cannot reach injuries and pain does not warn of damage, allowing lesions to expand silently until they become clinically serious.Cartilage lacks blood vessels, nerve fibres, and lymph channels, so repair cells cannot reach injuries and pain does not warn of damage, allowing lesions to expand silently until they become clinically serious.
ChondroFiller™ durability compared with ArthrosamidChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
Medial knee pain that isn't a meniscus tearAround 850,000 meniscal surgeries are performed annually in the United States, yet five other structures in the medial knee generate pain so similar that clinicians commonly mistake them for meniscal tears.Around 850,000 meniscal surgeries are performed annually in the United States, yet five other structures in the medial knee generate pain so similar that clinicians commonly mistake them for meniscal tears.
ChondroFiller versus hyaluronic acid for cartilage defectsChondroFiller fills discrete cartilage defects using a cell-recruiting scaffold; hyaluronic acid treats diffuse osteoarthritis through joint lubrication. They address different pathologies, and the choice depends on imaging, not on how much pain a patient experiences.ChondroFiller fills discrete cartilage defects using a cell-recruiting scaffold; hyaluronic acid treats diffuse osteoarthritis through joint lubrication. They address different pathologies, and the choice depends on imaging, not on how much pain a patient experiences.
Who qualifies for ChondroFiller Liquid Cartilage injectionChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.ChondroFiller is an outpatient ultrasound-guided injection—not surgery—of acellular collagen that recruits the patient's own progenitor cells to regenerate cartilage damage, without upper age or defect-size limits.
The cost of leaving a knee cartilage defect untreatedKnee cartilage defects do not heal because cartilage lacks blood supply; defects widen under load with each step, spreading damage to surrounding tissue and progressing towards osteoarthritis if untreated.Knee cartilage defects do not heal because cartilage lacks blood supply; defects widen under load with each step, spreading damage to surrounding tissue and progressing towards osteoarthritis if untreated.
What ChondroFiller's CE approval means for UK patientsChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.ChondroFiller recruits the body's progenitor cells to repair focal cartilage defects, achieving symptom relief in 70–85% of selected patients, though it offers no benefit for widespread osteoarthritis.
Who qualifies for a ChondroFiller injectionChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.ChondroFiller targets ICRS Grade III–IV cartilage damage, where more than half the cartilage is lost or bone is exposed. Delivered as an ultrasound-guided outpatient injection, the collagen scaffold recruits the patient's own progenitor cells to initiate repair.
When hip pain needs a specialistHip pain persisting beyond two weeks, disrupting sleep or preventing stairs and dressing, warrants GP assessment; specialist referral typically requires prior documentation of 8–12 weeks of conservative management.Hip pain persisting beyond two weeks, disrupting sleep or preventing stairs and dressing, warrants GP assessment; specialist referral typically requires prior documentation of 8–12 weeks of conservative management.
When cartilage repair makes sense before knee replacementTotal knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.Total knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.
How long ChondroFiller results lastChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.ChondroFiller's collagen scaffold biodegrades within 6–24 months, yet provides lasting clinical benefit by recruiting the patient's own cells to form repair tissue; 70–85% of well-selected patients maintain meaningful symptom relief at three to five years.